北京昭衍新药研究中心股份有限公司（股票代码：06127）于2026年7月3日发布2026年6月股份变动月报表，就截至2026年6月30日的股本结构及变化进行披露。
公告显示，昭衍新药拥有普通股H股118,995,206股，普通股A股630,353,014股，两类股份合计749,348,220股。本月底法定/注册股本总额为人民币7.49亿元（根据公告披露的人民币749,348,220元数据换算为亿元）。本月期间，公司普通股A股与H股均无新增发行、股份购回或注销，股本数量保持不变，且无股份期权、权证、可转换债券及其他股份相关协议或安排的变动。
根据公告，昭衍新药的H股已满足香港联交所适用的公众持股量要求。公司亦声明各类证券发行、上市及持有情况均经董事会审批并遵守香港联交所《上市规则》和相关法律法规。公告由联席公司秘书高大鹏代表公司签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.